These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 30518981)

  • 1. Chemotherapy plus DLI for relapse after haploidentical HSCT: the biological characteristics of relapse influences clinical outcomes of acute leukemia patients.
    Sun W; Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
    Bone Marrow Transplant; 2019 Aug; 54(8):1198-1207. PubMed ID: 30518981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salvage chemotherapy followed by granulocyte colony-stimulating factor-primed donor leukocyte infusion with graft-vs.-host disease control for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: prognostic factors and clinical outcomes.
    Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
    Eur J Haematol; 2016 Mar; 96(3):297-308. PubMed ID: 26010204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of chemotherapy combined with donor lymphocyte infusion on chronic graft-versus-host disease and prognosis in minimal residual disease positive patients after allogeneic hematopoietic stem cell transplantation].
    Shi YX; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YY; Liu KY; Huang XJ; Mo XD
    Zhonghua Xue Ye Xue Za Zhi; 2019 Sep; 40(9):713-719. PubMed ID: 31648470
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of outcomes after donor lymphocyte infusion with or without prior chemotherapy for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
    Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
    Ann Hematol; 2017 May; 96(5):829-838. PubMed ID: 28285386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: superior outcomes compared with chemotherapy alone and an analysis of prognostic factors.
    Yan CH; Wang JZ; Liu DH; Xu LP; Chen H; Liu KY; Huang XJ
    Eur J Haematol; 2013 Oct; 91(4):304-14. PubMed ID: 23837640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-α: A Potentially Effective Treatment for Minimal Residual Disease in Acute Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation.
    Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1939-47. PubMed ID: 26116088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Occurrence and Severity of Donor Lymphocyte Infusion-Associated Chronic Graft-versus-Host Disease Influence the Clinical Outcomes in Relapsed Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation.
    Yu WJ; Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
    Biol Blood Marrow Transplant; 2019 May; 25(5):912-920. PubMed ID: 30485788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential intensified conditioning followed by prophylactic DLI could reduce relapse of refractory acute leukemia after allo-HSCT.
    Xuan L; Fan Z; Zhang Y; Zhou H; Huang F; Dai M; Nie D; Lin D; Xu N; Guo X; Jiang Q; Sun J; Xiao Y; Liu Q
    Oncotarget; 2016 May; 7(22):32579-91. PubMed ID: 27081039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of T Cell Exhaustion by the First Donor Lymphocyte Infusion Is Associated with the Persistently Effective Antileukemic Responses in Patients with Relapsed AML after Allo-HSCT.
    Liu L; Chang YJ; Xu LP; Zhang XH; Wang Y; Liu KY; Huang XJ
    Biol Blood Marrow Transplant; 2018 Jul; 24(7):1350-1359. PubMed ID: 29649617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the safety and efficacy of prophylactic donor lymphocyte infusion after haploidentical versus matched-sibling PBSCT in very high-risk acute myeloid leukemia.
    Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
    Ann Hematol; 2019 May; 98(5):1267-1277. PubMed ID: 30747249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloablative Haploidentical Transplantation Is Superior to Chemotherapy for Patients with Intermediate-risk Acute Myelogenous Leukemia in First Complete Remission.
    Lv M; Wang Y; Chang YJ; Zhang XH; Xu LP; Jiang Q; Jiang H; Lu J; Chen H; Han W; Wang FR; Wang JZ; Chen Y; Yan CH; Zhang YY; Sun YQ; Mo XD; Zhu HH; Jia JS; Zhao T; Wang J; Liu KY; Huang XJ
    Clin Cancer Res; 2019 Mar; 25(6):1737-1748. PubMed ID: 30478089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donor lymphocyte infusion for the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.
    Takami A; Yano S; Yokoyama H; Kuwatsuka Y; Yamaguchi T; Kanda Y; Morishima Y; Fukuda T; Miyazaki Y; Nakamae H; Tanaka J; Atsuta Y; Kanamori H
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1785-90. PubMed ID: 25034960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy analysis of unrelated donor hematopoietic stem cell transplantation for treatment of high risk acute myeloid leukemia].
    Ye F; Tang XW; Sun AN; Qiu HY; Jin ZM; Fu ZZ; Chen F; Wu DP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):696-701. PubMed ID: 23815925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Outcome of haploidentical hematopoietic stem cell transplantation for refractory/relapsed acute leukemia].
    Wang Y; Liu DH; Liu KY; Xu LP; Zhang XH; Han W; Chen H; Chen YH; Wang FR; Wang JZ; Fu HX; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2012 Nov; 33(11):917-21. PubMed ID: 23363748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocyte infusions.
    Ortí G; Sanz J; García-Cadenas I; Sánchez-Ortega I; Alonso L; Jiménez MJ; Sisinni L; Azqueta C; Salamero O; Badell I; Ferra C; de Heredia CD; Parody R; Sanz MA; Sierra J; Piñana JL; Querol S; Valcárcel D
    Exp Hematol; 2018 Jun; 62():24-32. PubMed ID: 29526774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis.
    Chang YJ; Wang Y; Liu YR; Xu LP; Zhang XH; Chen H; Chen YH; Wang FR; Han W; Sun YQ; Yan CH; Tang FF; Mo XD; Liu KY; Huang XJ
    J Hematol Oncol; 2017 Jul; 10(1):134. PubMed ID: 28676064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party.
    Schmid C; Labopin M; Nagler A; Bornhäuser M; Finke J; Fassas A; Volin L; Gürman G; Maertens J; Bordigoni P; Holler E; Ehninger G; Polge E; Gorin NC; Kolb HJ; Rocha V;
    J Clin Oncol; 2007 Nov; 25(31):4938-45. PubMed ID: 17909197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT.
    Santoro N; Labopin M; Giannotti F; Ehninger G; Niederwieser D; Brecht A; Stelljes M; Kröger N; Einsele H; Eder M; Hallek M; Glass B; Finke J; Ciceri F; Mohty M; Ruggeri A; Nagler A
    J Hematol Oncol; 2018 Apr; 11(1):55. PubMed ID: 29661208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunosuppression for 6-8 weeks after modified donor lymphocyte infusion reduced acute graft-versus-host disease without influencing graft-versus-leukemia effect in haploidentical transplant.
    Yan C; Xu L; Liu D; Chen H; Wang Y; Liu K; Huang X
    Chin Med J (Engl); 2014; 127(20):3602-9. PubMed ID: 25316237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical study on the relapsd leukemia patients with graft versus host disease after allogeneic hematopoietic stem cell transplantation].
    Zhang XH; Fu HX; Liu KY; Xu LP; Liu DH; Chen H; Han W; Chen YH; Wang FR; Wang JZ; Zhao T; Wang Y; Chen Y; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2010 May; 31(5):323-7. PubMed ID: 21122312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.